



ASX ANNOUNCEMENT

17 June 2025

## **Translational data shows persistence of CHM CDH17**

- **Dose level 1 has completed enrolment and provides validating translational information**
- **CHM CDH17 expansion and persistence observed in all subjects treated at Dose Level 1**
- **Dosing of subjects to Dose Level 2 is ongoing**

Melbourne, Australia, 17 June 2025: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), is pleased to announce that translational analysis shows CHM CDH17 CAR-T cells can persist for several months in cancer patients after a single infusion.

The Phase 1/2 trial of CHM CDH17 is evaluating its effect in advanced gastrointestinal (GI) cancer subjects, and has shown expansion and persistence of CHM CDH17 CAR-T cells up to 28 days in all 4 subjects treated at dose level 1. Two subjects with prolonged stable disease have demonstrated measurable CAR-T cells in their circulation for up to six months after a single infusion.

CHM CDH17 CAR-T cells target cadherin 17, a cell surface protein that is dysregulated and overexpressed in gastrointestinal tumours. Immunohistochemistry data of the 4 subjects at dose level 1 confirm the presence of the target, cadherin 17, on the surface of the tumour cells of all the study subjects.

“Although this translational dataset represents only a small number of clinical trial subjects, CAR-T expansion and persistence is highly validating for CHM CDH17 and increases our confidence as we advance through clinical dose finding,” said Dr Rebecca McQualter, CEO of Chimeric Therapeutics.

The Phase 1/2 trial (NCT06055439) is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours (NETs). CHM CDH17 is a 3rd generation, novel CAR-T cell therapy that targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumours.

The Phase 1 portion of this study is expected to enrol up to 15 patients and lead to dose selection and expansion with indication-specific Phase 2 cohorts.



## **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, a clinical stage cell therapy company is focused on bringing the promise of cell therapy to life for more patients with cancer.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, Professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated.

CHM CLTX is a novel CAR-T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

*Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.*



**Contact**

Investors

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: [investors@chimerictherapeutics.com](mailto:investors@chimerictherapeutics.com)

W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)